Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NV-387's unique host-mimetic mechanism makes it potentially effective against various viruses while being difficult for viruses to develop resistance, positioning it as a potentially revolutionary treatment comparable to penicillin's impact on bacterial infections.
NanoViricides (NYSE:NNVC) is advancing its broad-spectrum antiviral drug NV-387 to combat multiple viral threats. The company is targeting two major opportunities: Measles, where cases have increased 10-fold in Europe with concerning vaccine failure rates, and MPox, which remains a Public Health Emergency of International Concern according to WHO.
The company has initiated an animal efficacy study for Measles and received clearance from DRC's National Ethics Committee to proceed with Phase II Clinical Trial for MPox treatment. NV-387 will be available to licensed physicians for treating Measles cases under FDA's Individual Patient Expanded Access protocol.
Additionally, NanoViricides is developing NV-387 as an "emperic" treatment for respiratory viral infections through a "basket-type" clinical trial targeting All Influenzas, All Coronaviruses, and RSV. The company is also developing NV-HHV-1, a pan-herpesvirus drug targeting infections linked to neurological damage and Alzheimer's disease.
NanoViricides (NYSE: NNVC), a clinical-stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. Company President & Executive Chairman Anil R. Diwan will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.
NanoViricides announces progress in developing a potential treatment for measles as the disease threatens to become endemic in the USA. The company's drug candidate NV-387, a broad-spectrum antiviral, shows promise in targeting measles and related viruses like RSV.
Key developments:
- Stanford scientists predict measles becoming endemic due to declining vaccination rates
- 884 confirmed measles cases reported across 30 jurisdictions as of April 24, 2025
- 11% hospitalization rate with 3 fatalities
- NV-387 completed Phase I trials with no adverse events
- Company acquired measles virus and plans animal model studies
The company highlights vaccination challenges, including public trust issues post-COVID-19 and increasing population segments ineligible for vaccines. NV-387's mechanism mimics HSPG to act as a viral decoy, potentially effective against multiple viruses including measles, RSV, influenza, and COVID-19.
NanoViricides (NYSE:NNVC) has announced the evaluation of its clinical drug NV-387 for treating Measles virus amid a growing outbreak. The drug, which has completed Phase I trials with no adverse events, has shown effectiveness against multiple viruses that use HSPG for infection, including RSV, COVID-19, Influenza, and MPox.
According to CDC data as of April 11, 2025, there are 712 confirmed Measles cases, with 79 hospitalizations (11%) and 3 deaths. The company is open to enabling NV-387's use under FDA's 'Emergency Expanded Access for an Individual Patient' protocols. NanoViricides plans additional laboratory studies to evaluate NV-387's effectiveness against Measles in cell culture and animal models to support a future IND application.
The company argues that vaccination alone may not be sufficient to control outbreaks, citing a 28% vaccine failure rate among hospitalized cases and the need for 95-97% coverage for herd immunity.
NanoViricides (NYSE:NNVC) addresses recent stock price decline, emphasizing its immunity to tariffs and government spending cuts. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral showing promise against multiple viruses including measles, RSV, MPox, and influenza.
The company is preparing for a Phase II clinical trial of NV-387 for MPox treatment in Central Africa. NV-387's unique mechanism mimics host-side signatures that viruses target, potentially effective against 90% of human pathogenic viruses. The company also highlights NV-HHV-1, their herpesvirus antiviral candidate, and NV-HIV-1 for HIV/AIDS treatment.
Management believes the recent stock decline alongside market sell-off is misguided, positioning NNVC as a potential hedge against market turmoil due to its strong long-term prospects in antiviral drug development.
NanoViricides (NNVC) announces its drug candidate NV-387 as a potential treatment for the ongoing measles outbreak, addressing HHS Secretary Kennedy's concern about the lack of approved antivirals. The broad-spectrum antiviral has shown effectiveness against various viruses that use heparan sulfate proteoglycans (HSPG) during cell infection.
The company believes NV-387 could be effective against measles based on two key factors: (1) studies indicating measles virus uses HSPG during cell infection, and (2) its success in treating RSV, which belongs to the same virus family as measles. NanoViricides proposes an investigator-initiated clinical trial to evaluate NV-387 as a measles treatment within FDA regulatory framework.
The announcement comes amid concerns about vaccine effectiveness against new measles variants, with the current Texas outbreak showing that even some vaccinated children are being hospitalized. The outbreak strain (genotype D.8) differs from the vaccine strain (genotype A), highlighting the need for effective treatment options.
NanoViricides (NYSE:NNVC) has filed its Q4 2024 quarterly report, highlighting its progress with NV-387, a broad-spectrum antiviral drug. The company reported $3.96M in cash and equivalents, with $7.17M in net property and equipment assets. Total current liabilities were $1.18M.
The company is preparing for Phase II clinical trials of NV-387 to treat MPox infection in Central Africa, where clinical trial sites have been identified. NV-387 successfully completed Phase Ia/Ib trials with no adverse events. The drug has shown promising results against various viruses, including Bird Flu H5N1, RSV, Influenza, and MPox.
However, NNVC reported insufficient funding to continue operations through February 14, 2026, for planned objectives. The company raised approximately $4M through an ATM offering and has access to a $3M credit line from its founder.